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INTRODUCTION
Natriuretic peptides (NPs) have become an essen-
tial aid to establish a proper diagnosis and prognosis 
and to monitor patients with heart failure (Dickstein 
et al., 2008). Atrial and brain NPs are the two most 
important members of the NP family, which contains 
a typical 17-amino acid ring closed by a disulfide 
binding between two cysteine-molecules (Stein and 
Levin, 1998). Both atrial and brain NPs are released 
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SAMENVATTING
“Brain natriuretic peptide” (BNP) wordt gebruikt in de humane geneeskunde voor de diagnose 
van congestief hartfalen. Vermits er geen BNP-test voor paarden beschikbaar is, werd BNP nog nooit 
bepaald bij paarden. Op basis van de 90% homologie tussen equine en porciene BNP, werd in de voor-
liggende studie het plasma BNP-gehalte van gezonde paarden (groep 1; n=20), paarden met een hart-
aandoening zonder (groep 2a; n=8) en met atriale dilatatie (n=8), ventriculaire dilatatie (n=1) of beide 
(n=1) (groep 2b; n=10) bepaald met een porciene BNP “enzyme-linked immunoassay” (ELISA). Er 
werd geen significant verschil gevonden tussen de BNP-concentratie van groep 1 (77,79; 37,20-513,36 
pg/mL), groep 2a (52,02; 24,69-268,37 pg/mL) of 2b (94,73; 42,88-470,66 pg/mL). In deze pilootstu-
die wordt aangetoond dat deze porciene BNP ELISA-test geen accurate detectie van BNP bij paarden 
toelaat. Een specifieke equine BNP-test zou dus ontwikkeld moeten worden om de BNP-concentratie 
bij paarden te meten.
     BSTRACT
Brain natriuretic peptide (BNP) is used in human medicine for the diagnosis of congestive 
heart failure. Since BNP is species-specific and no equine assay is available, BNP has never been 
determined in horses. Because there is more than 90% homology between porcine and equine 
BNP, a porcine BNP enzyme-linked immunoassay (ELISA) was used in the present study to 
measure BNP in plasma of healthy horses (group 1; n=20), horses with cardiac disease without 
(group 2a; n=8) and with atrial dilatation (n=8), ventricular dilatation (n=1) or both (n=1) (group 
2b; n=10). Samples were stored at -20°C and -80°C to study the influence of storage temperature. 
No significant differences were found between the BNP concentrations of group 1 (77.79; 37.20-
513.36 pg/mL), group 2a (52.02; 24.69-268.37 pg/mL) or 2b (94.73; 42.88-470.66 pg/mL). Samples 
stored at -80°C showed significantly (72.19, 24.69-513.36 pg/mL; P=0.001) higher concentrations 
than samples stored at -20°C (47.35, 24.69-430.60 pg/mL). In this pilot study, it is suggested that 
the porcine BNP assay does not allow accurate detection of equine BNP. An equine specific BNP 
assay should be developed to study BNP concentrations in horses.
A
in case of cardiac dilatation and subsequently broken 
down into a stable, inactive NH2-terminal molecule 
(NT-proANP and NT-proBNP) and an unstable, ac-
tive molecule (ANP and BNP). Atrial NPs are mainly 
secreted in case of atrial dilatation (Hayek and Nemer, 
2010; Hori et al., 2011; Trachsel et al., 2012), while 
brain NPs are more related with ventricular patholo-
gies (Goetze, 2004). Due to their longer half-life, brain 
NPs are often preferred for the diagnosis of heart fail-
ure in human clinical practice (Woodard and Rosado, 
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2007; Ray et al., 2008). A half-life of 2-5 min (Rus-
koaho, 1992) and of 55-60 min (Ikeda et al., 2007) 
have been reported for human ANP and NT-proANP, 
respectively, while BNP and NT-proBNP have a half-
life of 12-20 min and 60-120 min, respectively (Pem-
berton et al., 2000; Kemperman et al., 2004; Kimura 
et al., 2007; Kroll et al., 2007). 
Human and equine ANP have 100% homology 
(Van Der Vekens et al., 2013). This explains why 
ANP has already been successfully determined in 
horses using human assays. A significant correlation 
between ANP plasma levels and left atrial dilatation 
has already been demonstrated (Gehlen et al., 2007; 
Trachsel et al., 2012; Trachsel et al., 2013; Trachsel et 
al., 2014). In contrast to ANP, the molecular structure 
of BNP and NT-proBNP is more variable amongst 
species (Van Der Vekens et al., 2013). Recently, a 
new canine and feline NT-proBNP assay (Cardiopet, 
IDEXX, Hoofddorp, the Netherlands) has been de-
veloped and successfully used for the detection of 
cardiac disease in dogs and cats (Oyama and Single-
tary, 2010; Tominaga et al., 2011; Hassdenteufel et 
al., 2013). However, equine studies regarding brain 
NPs are still missing. Since NT-proBNP has a longer 
half-life and is currently clinically the most important 
molecule in dogs and cats (Oyama, 2013), equine NT-
proBNP measurement might be the best choice for 
future use in clinical practice. However, compared to 
NT-proBNP, the shorter BNP molecule seems to have 
more homology between some species (Van Der Ve-
kens et al., 2012). Therefore, similarly to ANP, only 
for BNP, there is a chance that assays validated for 
other species might be useful to detect equine BNP. 
Human and equine BNP have ±75 % homology (Van 
Der Vekens et al., 2013). Hence, successful use of hu-
man BNP assays in horses seems unlikely. The dif-
ference between equine and porcine BNP is much 
smaller: only 3 of the 32 amino-acids of porcine and 
equine BNP differ (Van Der Vekens et al., 2013) (Ta-
ble 1). Thus, a porcine assay might be suitable for the 
measurement of BNP in horses. Brain NP-like activity 
has been demonstrated in equine atrial tissue using 
antiserum against porcine BNP (Mifune et al., 1995), 
but a porcine BNP assay has never been used to mea-
sure BNP in horse plasma. The objectives of this 
pilot study were (1) to use a porcine BNP assay for 
the measurement of BNP in plasma of healthy horses 
and horses with cardiac disease and (2) to determine 
whether sample storage temperature has an important 
effect on analysis results.
MATERIALS AND METHODS
Study population
The study was approved (EC2012/57) by the ethi-
cal committee of the Faculty of Veterinary Medicine 
and Bioscience Engineering of Ghent University. All 
horses were privately owned and all examinations 
were performed with the owner’s informed consent. 
The study population consisted of 20 healthy horses 
(group 1) and 18 horses with cardiac disease (group 
2). The horses of group 1 were subjected to a thor-
ough examination, including medical assessment of 
case history, clinical examination, echocardiographic 
examination and registration of electrocardiography 
(ECG) at rest and during a standardized lunging exer-
cise test, which consisted of a five-minute walk, a ten-
minute trot, a four-minute canter and a one-minute 
gallop (Verheyen et al., 2013). In order to be included 
in group 1, the horses had to be healthy, trained 2-4 
times a week and had to be free of cardiorespiratory 
disease. 
The horses of group 2 were presented at the Faculty 
of Veterinary Medicine, Ghent University (Merel-
beke, Belgium) with a cardiac murmur. Only horses, 
in which moderate to severe regurgitation at one or 
more cardiac valves could be visualized by means of 
cardiac ultrasound, were included. All horses of this 
group underwent echocardiography and ECG record-
ing. Based on echocardiographic measurements, the 
horses were classified into two subgroups: group 2a 
included the horses with valvular regurgitation with-
out cardiac dilatation and group 2b included the horses 
with valvular regurgitation and either atrial dilatation 
or ventricular dilatation or both.
Echocardiographic measurements
Transthoracic echocardiographic examination in-
cluded two-dimensional B-mode, M-mode and color 
Doppler (GE Vivid 7 Dimension, GE Healthcare, Die-
gem, Benelux) using a phased-array transducer (3S 
Phased Array Transducer, GE Healthcare, Diegem, 
Benelux) at a frequency of 1.7/3.4 MHz. A modified 
base-apex ECG was recorded simultaneously and at 
least three cardiac cycles from each view were stored. 
Off-line analysis was performed using dedicated soft-
ware (EchoPAC software version 12, GE Healthcare, 
Diegem, Benelux). For each parameter, the average 
of three cardiac cycles was determined. The left atrial 
Table 1. Comparison of the amino-acid sequence of equine and porcine brain natriuretic peptide. The amino-acids in 
red are different between horses and pigs.
Brain natriuretic peptide
                
Equine S P K M M R N S G C F G R R L D R I G S F S G L G C N V L R R Y
Porcine S P K T M R D S G C F G R R L D R I G S L S G L G C N V L R R Y
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size was evaluated by the measurement of the end-
systolic left atrial-to-aortic root diameter ratio (LA/
Ao) from a short axis image. The short axis systolic 
diameter of the left atrium (LA) was measured by 
placing two calipers in a line extending from and par-
allel to the commissure between the non-coronary and 
left coronary aortic valve cusps to the distant margin 
of the left atrium. The internal short axis diameter of 
the aorta at valvular level was determined by placing 
calipers along the commissure between the non-coro-
nary and right coronary aortic valve cusps (De Clercq 
et al., 2008). If the LA/Ao was > 1.25, the horses were 
diagnosed as having atrial dilatation and thus catego-
rized in group 2b. Similarly, ventricular dilatation was 
evaluated by the measurement of the left ventricular 
internal diameter during diastole (LVIDd) from a 
short-axis M-mode view of the left ventricle at chord-
al level. Horses with a LVIDd >13.30 cm were con-
sidered having left ventricular dilatation (Grenacher 
and Schwarzwald, 2010), and therefore categorized 
in group 2b. A subjective assessment of the dimen-
sions of the right atrium and the right ventricle was 
performed on a long axis four chamber view.  
Blood sampling and analysis
Two ethylenediaminetetraacetic acid (EDTA) 
tubes with aprotinin (Vacutainer 1.6 mg K3 EDTA 
and 50 KIU aprotinin/mL blood, BD diagnostics, 
Erembodegem, Belgium) were collected by punc-
ture of the jugular vein with a venoject (Venosafe, 
Terumo Europe, Leuven, Belgium). Aprotinin (Buck-
ley et al., 1999) is a proteinase inhibitor that might 
improve sample stability. From ten healthy horses, 
EDTA samples without aprotinin were also collected 
and stored at -80°C to study the influence of this pro-
teinase inhibitor. The blood samples were directly 
stored on ice and centrifuged (1000g, 15 min, 2-8°C) 
within 30 minutes. Next, the plasma was harvested 
and transferred into two cryovials (Cryovials, 2 mL, 
VWR international, Pennsylvania, USA). One cryo-
vial was stored at -80°C and one at -20°C until analy-
sis. Time until analysis was 1 (1-2) day in group 1,7 
(1-17) days in group 2a and 9 (1-31) days in group 
2b. Sample analysis was performed with a porcine 
competitive inhibition enzyme-linked immunoassay 
(ELISA, E90541Po, Uscn, Wuhan, China), in which 
a monoclonal antibody, specific for porcine BNP, was 
pre-coated on the plate and attached to BNP pres-
ent in the sample. Next, biotin-labeled porcine BNP 
was added, which began a competition with the BNP 
present in the sample. Finally, avidin bound to horse 
radish peroxidase and 3.3′, 5.5′-tetramethylbenzidine 
(TMB) substrate were added to establish a color reac-
tion. The intensity of the color reaction was reverse 
proportional to the BNP concentration in the sample. 
The inter-assay and intra-assay coefficients of varia-
tion (CV) were <12% and <10% according to the 
manufacturer’s instructions. The detection range was 
between 24.69 and 2000.00 pg/mL. For the analysis 
of all 76 samples (38 samples stored at two differ-
ent temperatures), three different ELISA plates were 
used. All samples were analyzed in duplicate and the 
samples from the horses of each group were included 
in each plate. For each horse, the -20°C and -80°C 
samples were analyzed within the same plate to avoid 
inter-assay variation in order to allow comparison of 
storage temperature. 
Statistical analysis
Data analysis was performed using commer-
cially available computer software (SPSS Statistics 
22.0, Chicago, IL). The level of significance was set 
at P=0.05. The Kolmogorov-Smirnov and Shapiro-
Wilk tests were used to test normal distribution of 
data. Normally distributed data were expressed as 
mean±standard deviation and non-parametric data 
were expressed as median (range). The mean age and 
weight of groups 1 and 2 were compared by a student’s 
t-test for independent samples. The median BNP con-
centration and the storage time between groups were 
compared by a Mann Whitney U-test. Comparison 
between the BNP concentration of samples stored at 
-20°C and -80°C and of samples with and without 
aprotinin was done by the Wilcoxon signed rank test. 
The influence of the storage temperature was further 
studied by Bland Altman analysis. Samples with a 
concentration under the limit of detection (<24.69 pg/
mL) were assigned the value of the limit of detection. 
The association between BNP and echocardiographic 
measurements was examined by the Spearman cor-
relation coefficient (P=0.01). 
RESULTS
Clinical, echocardiographic and electrocardio-
graphic examination
Group 1 consisted of 20 Warmblood horses: 10 
geldings, 9 mares and 1 stallion (age: 8±4 years, 
weight: 563±52 kg, height: 168±5 cm). The LA/Ao 
and LVIDd were 1.15±0.05 and 11.33±1.19 cm, re-
spectively. The exercise ECG was normal in 18/20 
horses. One horse had one atrial premature depolar-
ization (APD) and another horse had two ventricular 
premature depolarizations (VPDs) during exercise.
Group 2 consisted of 14 Warmblood horses, 1 Ara-
bian horse, 1 Friesian, 1 Spanish horse and 1 mixed 
breed and included 8 geldings, 8 mares and 2 stallions 
(age: 13±6 years, weight: 566±90 kg; height: 167±9 
cm). The mean age (P=0.006) in group 2 was signifi-
cantly higher than the mean age in group 1. No dif-
ference in weight was found. A systolic murmur was 
detected in 13/18 horses and a diastolic murmur in 
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6/18 horses. Echocardiographic examination demon- 
strated a moderate or severe regurgitation of one 
(n=13) or more valves (n=5) in all of the horses. The 
mitral valve was mostly affected (n=10), followed 
by the aortic (n=7), tricuspid (n=4) and pulmonary 
valve (n=2). Two horses also showed a ventricular 
septal defect and one Friesian was diagnosed with 
an aortopulmonary fistula. Based on the LA/Ao and 
the LVIDd, eight horses had normal left atrial and 
left ventricular diameters and were categorized in 
group 2a. One horse had a markedly enlarged right 
atrium, and was therefore classified in group 2b. The 
remaining nine horses had a LA/Ao>1.25 (n=8) or a 
LVIDd>13.30 (n=2), and were therefore categorized 
in group 2b. The mean LA/Ao and LVIDd in group 2a 
were 1.16±0.06 and 12.41±0.83 cm, respectively. A 
mean LA/Ao of 1.40±0.18 and LVIDd of 12.53±1.54 
was demonstrated in group 2b. Electrocardiographic 
examination demonstrated atrial fibrillation in three 
horses. An exercise ECG was performed in 15/18 
horses. No abnormalities were found in 4/15 horses. 
Six horses had between one and nine APDs and eight 
horses between one and four VPDs during exercise. 
BNP comparison between groups
When samples were stored at -80°C (BNP-80), the 
median BNP concentration in group 1 was 77.79 pg/
mL (37.20-513.36) pg/mL. No significant (P=0.135) 
difference was found with the BNP-80 concentration of 
group 2a (52.02 pg/mL, range 24.69-268.37 pg/mL) or 
group 2b (94.73 pg/mL, range 42.88-470.66 pg/mL) 
(Figure 1). There was no correlation between the 
BNP-80 concentration and the LA/Ao or LVIDd (Table 2).
Influence of sample storage temperature and apro-
tinin addition
When samples were stored at -20°C (BNP-20), a sig-
nificantly (P<0.001) lower BNP concentration (47.35 
pg/mL, range 24.69-430.60 pg/mL) was found than 
when samples were stored at -80°C (72.19 pg/mL, 
range 24.69-513.36 pg/mL). Similarly as for BNP-
80, no significant (P=0.792) BNP-20 difference was 
found between group 1 (48.84 pg/mL, range 24.69-
139.63 pg/mL), group 2a (51.85 pg/mL, range 24.69-
430.60 pg/mL) or group 2b (40.80 pg/mL, range 
24.69-409.13 pg/mL) (Figure 2). A significant cor-
relation (P<0.01) existed between BNP-20 and BNP-80 
(Table 2). The mean difference between the BNP-80 
and BNP-20 concentrations was 62.69±149.61 pg/mL 
(Figure 3). Almost all (n=32) of the BNP samples 
stored at a temperature of -80°C had a higher concen-
tration than when stored at -20°C. 
The median BNP concentration was significantly 
(P=0.037) higher in EDTA samples with aprotinin 
(240.86, 95.15-513.36 pg/mL) than in EDTA samples 
without aprotinin (147.54, 75.27-227.98 pg/mL).
Figure 3. Bland-Altman plot showing the relationship be-
tween the difference (BNP-80 - BNP-20) of brain natriuretic 
peptide (BNP) relative to the mean BNP concentration 
when samples stored at -80°C and -20°C were analyzed at 
the same time (group 1= healthy horses; group 2a= horses 
with regurgitation without atrial/ventricular dilatation; 
group 2b= horses with regurgitation and atrial or ven-
tricular dilatation; BNP-80: BNP concentration stored at 
-80°C; BNP-20: BNP stored at -20°C).
Figure 1. Brain natriuretic peptide concentrations when 
samples were stored at -80°C (BNP-80) of group 1 (healthy 
horses), group 2a (horses with regurgitation without atrial 
or ventricular dilatation) and group 2b (horses with regur-
gitation with atrial or ventricular dilatation).
Figure 2. Brain natriuretic peptide concentrations when 
samples were stored at -20°C (BNP-20) of group 1 (healthy 
horses), group 2a (horses with regurgitation without atrial 
or ventricular dilatation) and group 2b (horses with regur-
gitation with atrial or ventricular dilatation).
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DISCUSSION
Human assays have been used for equine ANP 
(Gehlen et al., 2007; Trachsel et al., 2012; Trachsel et 
al., 2013) and NT-proANP measurement (Kokkonen 
et al., 2002) based on the interspecies sequence homo-
logy between molecules (Gehlen et al., 2007; Trach-
sel et al., 2012; Trachsel et al., 2013). A sequence ho-
mology of 100% and 80-90% has been described for 
equine ANP (Richter et al., 1998) and NT-proANP 
(Kokkonen, 2002), respectively. Since BNP and NT-
proBNP are species-specific molecules, and no equine 
BNP or NT-proBNP test exists, the determination of 
brain NPs in horses remains impossible. However, 
brain NPs determination might be helpful as screen-
ing or follow-up test for cardiac disease in horses, es-
pecially if cardiac ultrasound is not available. Since 
equine and porcine BNP have a more than 90% ho-
mology (Van Der Vekens et al., 2012), a competitive 
porcine BNP ELISA was used in an attempt to mea-
sure equine BNP. Firstly, normal values were deter-
mined in 20 healthy horses and a median BNP con-
centration of 77.79 (37.20-513.36 pg/mL) was found. 
In comparison to humans and small animals, the BNP 
concentration was unexpectedly high and had a broad 
range. However, the results of the present study should 
be interpreted with caution as the porcine BNP assay 
was not validated for use in horses. Different BNP 
cut-off values have been described depending on the 
disease, which has to be detected. In humans, a cut-off 
value of 17.9 pg/mL for the detection of left ventricu-
lar systolic dysfunction has been described (Mc-
Donagh et al., 1998). In dogs, a cut-off value of 23 pg/
mL (MacDonald et al., 2003), 24.6 (DeFrancesco et 
al., 2007) and 6.21 pg/mL (Oyama et al., 2007) has 
been described for the detection of cardiac disease, 
for the distinction between cardiac and non-cardiac 
dyspnea and for the detection of dilatory cardiomyo-
pathy, respectively. However, the clinical utility of 
BNP for the detection of cardiac disease in dogs has 
been questioned, since a lot of healthy dogs also have 
BNP concentrations above the cut-off value (Lee et 
al., 2011) and NT-proBNP measurement might be 
more useful for the detection of cardiac disease in 
clinical practice (Oyama, 2013). The maximal BNP 
concentration and the BNP range of these dogs were 
still lower than the values in the present study. Al-
though it is possible that the BNP concentration is 
higher in horses than in humans or dogs, also cross 
reactivity with other NPs, such as proBNP, 
NT-proBNP or other degradation products (Goetze, 
2004) may lead to increased BNP detection values. 
The presence of cross reactivity in BNP and NT-proB-
NP assays has also been described in human medicine 
and makes clinical interpretation of assay results chal-
lenging (Luckenbill et al., 2008). In dogs, this cross 
reactivity might be decreased in a second generation 
ELISA (Canine Cardiopet, IDEXX, Hoofddorp, the 
Netherlands), which uses specific capture and detec-
tion antibodies targeted against canine NT-proBNP 
epitopes (Fox et al., 2014). Heterophile antibodies can 
cause false positive reactions, and might therefore 
also explain the high BNP concentration in the pres-
ent study (Solter et al., 2008). However, a competitive 
ELISA was used and normally, heterophile antibodies 
are too weak to compete with the high affinity anti-
gens in these assays and cause only false positive re-
sults when sandwich ELISAs are used (Kaplan and 
Levinson, 1999). Another possibility is that the mono-
clonal antibodies did not attach to equine BNP. Al-
though there is only a limited difference between the 
sequence of equine BNP and porcine BNP (Table 1), 
it remains possible that the monoclonal antibodies of 
the porcine BNP assay were developed against a BNP 
region where the equine and porcine BNP amino-acid 
sequences differ. Since many samples had a BNP con-
centration above the limit of detection and because a 
significant difference between sample storage tem-
peratures was detected, it seems likely that the mono-
clonal antibodies did detect equine BNP or at least an 
equine BNP-like molecule. Cross reactivity with an-
other equine molecule might explain why no differ-
Table 2. Spearman correlation coefficients between brain natriuretic peptide concentrations stored at -80°C (BNP-80) 
and -20°C (BNP-20) and echocardiographic measurements (n = number of horses, LA/Ao: left atrial-to-aortic root ratio, 
LVIDd= left ventricle internal diameter during diastole, *= P<0.01).
  BNP-80 BNP-20 LA/Ao LVIDd
 BNP-80 1 X X X
 n 38 
 BNP-20 0.505* 1 X X
 n 38 38
 LA/Ao 0.096 -0.300 1 X
 n 37 37
 
 LVIDd 0.202 -0.112 0.123 1
 n 38 38 37 
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ence was found between horses of groups 1 and 2, and 
why no correlation with echocardiographic parame-
ters was found. Antibodies against porcine BNP have 
been used to detect BNP-like activity in atrial cardiac 
myocytes (Mifune et al., 1995). In the study by Mi-
fune et al. (1995), atrial natriuretic peptide reactivity 
was detected in these same myocytes. Therefore, a 
cross-reaction between ANP and the anti-BNP anti-
bodies could possibly explain the BNP immunoreac-
tivity, which was found with the anti-BNP antibodies. 
However, the hypothesis was tested and no such 
cross-reactivity could be detected (Mifune et al., 
1995). Another explanation for the lack of difference 
between groups and the wide BNP range in healthy 
horses is the presence of confounding factors. Age, 
gender and breed have been described to affect the 
BNP concentration: a higher BNP concentration has 
been found in older patients and in women (Redfield 
et al., 2002). Similarly, high NT-proBNP values have 
been found in Labrador retrievers and Newfoundland 
dogs (Sjostrand et al., 2014). A negative correlation 
between BNP and obesity has also been reported 
(Wang et al., 2004). However, in the present study, no 
correlation was found between the BNP concentration 
and gender, age or weight in the group of healthy 
horses. Since all healthy horses were Warmblood 
horses, the influence of breed could not been exam-
ined. However, 14/18 horses with cardiac disease 
were also Warmblood horses. Therefore, the influence 
of breed on the results seems limited. The difference 
in sample storage time might also influence results. 
The samples of group 1 were stored for a significantly 
shorter time than samples of groups 2a  and 2b. If the 
BNP concentration in samples of group 2a or 2b had 
been reduced due to longer storage, the BNP differ-
ence between healthy horses and horses with cardiac 
disease would have become smaller. However, ac-
cording to manufacturer’s instructions, samples can 
be stored for 2 months at -80°C, and the BNP concen-
tration in the present study seemed surprisingly high 
in comparison to other species. Therefore, the influ-
ence of sample storage seemed limited. The presence 
of a large inter-assay variability could also explain the 
results. The inter-assay CV was determined by the 
manufacturer for the porcine BNP molecule. A differ-
ent inter-assay CV may be applied when measuring 
equine BNP. A large inter-assay CV means that re-
peated measurement of the same samples gives differ-
ent results. Three different ELISA plates were used 
for analysis of all samples. If there had been a large 
inter-assay variation between the three plates, the dif-
ference between healthy horses and horses with car-
diac disease would have become smaller. Samples 
from healthy horses analyzed with plate 1 (n=9; 
190.57 pg/mL, range 95.15-513.36 pg/mL) had a very 
high BNP concentration in comparison to plates 2 
(n=9; 42.48 pg/mL, range 37.20-61.74 pg/mL) and 3 
(n=2; 69.10 pg/mL, range 44.35-93.84 pg/mL). When 
only samples from plates 2 and 3 were included in this 
study, a significant difference between horses with 
cardiac dilatation (94.37 pg/mL, range: 43.77-470.66 
pg/mL) and healthy horses (44.35 pg/mL, 37.20-
93.84 pg/mL, P=0.014), and between horses with 
dilatation and horses with regurgitation without dila- 
tation (49.56 pg/mL, 24.69-179.30 pg/mL, P=0.043) 
was found. However, a correlation with echocardio-
graphic measurements was still not found, and only a 
small number of horses were included (group 1= 11, 
group 2a= 7 and group 2b= 9). Therefore, from these 
results, it could not be concluded that BNP increases 
in case of cardiac dilatation. Finally, BNP is especial-
ly correlated to ventricular dilatation and most of the 
horses of group 2 had atrial dilatation. Only 2 of the 
10 horses of group 2b had ventricular dilatation. The 
BNP-80 concentrations of these horses were 88.79 and 
243.35 pg/mL. Therefore, future studies on BNP or 
NT-proBNP measurement in horses should include 
more horses with ventricular dilatation. 
Sample storage temperature had a strong influence 
on sample concentration: samples, which were stored 
at -80°C had a significantly (P<0.001) higher con-
centration than samples stored at -20°C. Since both 
samples from the same horse were analyzed on the 
same ELISA plate, the inter-assay CV could not have 
influenced these results. Previous studies in human 
medicine have also shown that BNP is unstable at 
-20°C (Mueller et al., 2004). As it is possible that in 
the present study, a BNP-like molecule was measured 
instead of BNP, it could not be determined whether 
the difference was fully attributable to BNP sample 
stability. 
This pilot study is the first, in which measurement 
of equine plasma BNP using a porcine assay was at-
tempted. The major limitation of the study was the 
use of a non-validated BNP assay. BNP-like immuno-
reactivity in the samples was measured but it was not 
proven whether it concerned BNP or not. The pos-
sible existence of peptide cross-reactivity, sample in-
stability and assay variability further complicated the 
results. These three factors should also be taken into 
account when measuring ANP and NT-proANP in 
horses. Currently, only one ANP assay validation 
study has been published (Trachsel et al., 2014) and 
shows that there is a high inter-assay variability and 
that different ANP assays are poorly comparable. 
Therefore, there is a need for a validated, species-spe-
cific equine BNP /NT-proBNP test and a reliable ANP 
or NT-proANP assay for the use in clinical practice. 
CONCLUSIONS
Brain natriuretic peptide-like activity was found 
in equine plasma samples using a porcine BNP assay. 
Despite the high homology (>90%) between equine 
and porcine BNP, the porcine BNP ELISA could not 
differentiate healthy horses from horses with cardiac 
disease, probably due to a high inter-assay CV and 
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cross-reactivity with other plasma proteins. A major 
limitation of the study is that a non-validated assay 
was used. Therefore, further studies on assay valida-
tion, imprecision and accuracy should be performed. 
Ideally, equine specific BNP and NT-proBNP assays 
should be developed in order to study horses with and 
without cardiac disease. 
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